X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma

Table 2 Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables

	n*	XIAP-C		Smac		XIAP-N
		PR	Pvalue	PR	Pvalue	PR	Pvalue
Age
<50	49	42(85.7%)		20(40.8%)		21(42.9%)
≥50	53		0.789		0.145		1.000
Size		44(83.0%)		14(26.4%)		23(43.4%)
≤5 cm	77	67(87.0%)		26(33.8%)		33(42.9%)
>5 cm	25	19(76.0%)	0.212	8(32.0%)	1.000	11(44.0%)	1.000
LN status
N₀	39	33(84.6%)		14(35.9%)		14(35.9%)
N_1-3	63	53(84.1%)	1.000	20(31.7%)	0.672	30(47.6%)	0.305
Grade
I	25	22(88.0%)		10(40.0%)		13(52.0%)
II-III	77	64(83.1%)	0.755	24(31.2%)	0.468	31(40.3%)	0.356
ER
positive	39	31(79.5%)		14(35.9%)		20(51.3%)
negative	63	55(87.3%)	0.401	20(31.7%)	0.672	24(38.1%)	0.221
PR
positive	44	36(81.8%)		18(40.9%)		23(52.3%)
negative	58	50(86.2%)	0.591	16(27.6%)	0.204	21(36.2%)	0.112
HER2
positive	94	78(83.0%)		34(36.2%)		41(43.6%)
negative	8	8(100.0%)	0.351	0(0.0%)	0.049	3(37.5%)	1.000
XIAP-N
positive	44	41(93.2%)		16(36.4%)		/
negative	58	44(75.9%)	0.030	18(31.0%)	0.672	/

n*: number of cases. PR: positive rate. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively. P-values (two sided) < 0.05 were highlighted in bold.

ISSN: 1746-1596